Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that serum irisin levels were significantly lower in patients with acne vulgaris compared to healthy controls and were negatively correlated with insulin resistance and disease severity.

This study reports that the Luce LDS 100 infrared light therapy shows positive hair growth results after one year in men and women with androgenetic alopecia.

This study utilized 3D ultra-high frequency ultrasound to effectively detect different disease phases of alopecia areata by visualizing hair follicle structures and identifying unique pathological signs, offering a promising non-invasive diagnostic tool that surpasses conventional methods.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.

This case report documents a rare instance of hair loss associated with isoniazid initiation in a 32-year-old male undergoing antitubercular treatment.

This tool was developed to enhance reproducibility and sensitivity in measuring partial hair regrowth in alopecia areata patients, particularly those undergoing JAK inhibitor therapy, using scalp photographs.

This review synthesizes cases of biopsy-confirmed alopecia areata occurring in patients using IL-17 or IL-23 inhibitors, suggesting the need for increased awareness and further investigation into this rare adverse event.

In this study using a mouse model, RIPK1 inhibitors were found to delay the onset of alopecia areata, reduce immune cell numbers in affected skin, and increase hair length, indicating a potential therapeutic role in preventing alopecia areata.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This review outlines the practical use of reflectance confocal microscopy in dermatology, detailing its applications and considerations for diagnosing various skin conditions, but reports no new findings.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

Raltegravir may cause hair loss in some patients.

In this mouse model study, researchers observed that RIPK1 inhibitors delayed the onset of alopecia areata by modulating immune cells, specifically dendritic and CD8+ T cells, and increased hair length in organ culture mimicking the condition.

This study found that RXR and RAR proteins were detectable in normal human skin, suggesting they may play a role in epidermal cell differentiation and hair and gland physiology.

In this study, prenatal exposure to a non-teratogenic dose of all-trans-retinoic acid showed no adverse effects on vibrissal follicle development in NMRI mice.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This study found that RXRα/RARγ heterodimers are necessary for retinoic acid-induced keratinocyte proliferation in the skin, while normal epidermal maintenance does not require RAR-mediated signaling.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

Hsa-miR-193a-5p is important in alopecia areata by promoting inflammation and involving specific genes in hair and immune function.

This review discusses the potential of optical techniques for diagnosing and treating oxidative stress-related hepatic ischemia-reperfusion injury, highlighting the need for non-invasive diagnostic methods and the anti-oxidative potential of optical therapies; it reports no new clinical results.

In this study, researchers characterized the retinal structure and function of the Oat^rhg mouse model of gyrate atrophy, finding localized atrophy without significant retina-wide functional impact, suggesting the model may be useful for testing new treatments using multimodal retinal imaging.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.